UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Holdings in DaVita Inc. (NYSE:DVA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 2.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 408,660 shares of the company's stock after selling 10,868 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.50% of DaVita worth $66,992,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in DVA. Transcendent Capital Group LLC acquired a new stake in shares of DaVita during the 3rd quarter valued at about $25,000. Blue Trust Inc. raised its position in DaVita by 58.6% during the second quarter. Blue Trust Inc. now owns 211 shares of the company's stock worth $29,000 after acquiring an additional 78 shares during the period. Family Firm Inc. acquired a new stake in shares of DaVita in the second quarter valued at about $43,000. Friedenthal Financial acquired a new position in shares of DaVita during the 2nd quarter worth about $48,000. Finally, Point72 Hong Kong Ltd acquired a new stake in DaVita in the 2nd quarter worth about $68,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at DaVita

In related news, CEO Javier Rodriguez sold 9,881 shares of the stock in a transaction on Friday, September 13th. The stock was sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the completion of the sale, the chief executive officer now directly owns 887,835 shares of the company's stock, valued at $144,583,929.75. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 2.00% of the company's stock.

Analysts Set New Price Targets

DVA has been the topic of a number of research analyst reports. Barclays lifted their price target on DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research report on Wednesday, August 7th. UBS Group lifted their price objective on DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research report on Thursday, August 8th. Finally, Truist Financial lifted their price target on DaVita from $165.00 to $175.00 and gave the stock a "hold" rating in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $161.80.

DaVita Trading Up 0.2 %

Shares of DVA stock traded up $0.26 on Tuesday, hitting $164.00. The stock had a trading volume of 523,448 shares, compared to its average volume of 819,248. The company's 50 day moving average price is $158.62 and its 200-day moving average price is $149.67. DaVita Inc. has a 1 year low of $103.40 and a 1 year high of $169.51. The firm has a market capitalization of $13.45 billion, a P/E ratio of 17.72, a P/E/G ratio of 0.92 and a beta of 0.90. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing the consensus estimate of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to analysts' expectations of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. The business's quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the business earned $2.85 EPS. Analysts anticipate that DaVita Inc. will post 9.71 earnings per share for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.